financetom
Business
financetom
/
Business
/
S&P Assigns Rating to Dye & Durham; Down Nearly 1%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
S&P Assigns Rating to Dye & Durham; Down Nearly 1%
Mar 22, 2024 7:54 AM

10:31 AM EDT, 03/22/2024 (MT Newswires) -- S&P Global Ratings said Thursday that it has assigned its B issuer credit rating to Dye & Durham Ltd. ( DYNDF ) .

This reflects its relatively small scale, operations in a niche segment of the legal industry, adjusted debt-to-EBITDA of about 6.3x, and concentrated ownership while acknowledging the company's diverse customer base and track record of high margins and steady free cash flow generation, the rating agency said.

At the same time, the agency assigned its B issue-level rating to the company's proposed $495 million of seven-year senior secured term loan B and $680 million of other secured debt.

"The stable outlook reflects our expectations that the company's revenues and EBITDA will benefit from increasing transaction volumes as well as growing annual recurring revenue (ARR). The rating also captures management's ambitious growth strategy," S&P said.

The company's stock slipped nearly 1% on last look on Friday.

Price: 15.43, Change: -0.19, Percent Change: -1.22

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Drugs Made In America Acquisition Prices $200 Million IPO
Drugs Made In America Acquisition Prices $200 Million IPO
Jan 28, 2025
04:49 AM EST, 01/28/2025 (MT Newswires) -- Drugs Made In America Acquisition (DMAA) said late Monday it priced an initial public offering of 20 million units at $10 each. The company granted the underwriter a 45-day option to purchase up to an additional 3 million units. Each unit consists of one ordinary share and one right to receive one-eighth of...
Update: Chevron Cabinda Gulf Operations Resume After Release of Oil
Update: Chevron Cabinda Gulf Operations Resume After Release of Oil
Jan 28, 2025
04:58 AM EST, 01/28/2025 (MT Newswires) -- (Updates with attribution to Chevron ( CVX ) throughout and additional information in the last two paragraphs.) Chevron ( CVX ) said its Cabinda Gulf Oil operations in Angola have resumed normal operations after an oil sheen and debris were found nearby along the Atlantic Ocean coastline. About five barrels of oil were...
AstraZeneca, Daiichi Sankyo's Enhertu Gets US FDA Approval for Treatment of Inoperable Breast Cancers
AstraZeneca, Daiichi Sankyo's Enhertu Gets US FDA Approval for Treatment of Inoperable Breast Cancers
Jan 28, 2025
04:57 AM EST, 01/28/2025 (MT Newswires) -- AstraZeneca ( AZN ) and Daiichi Sankyo said their drug Enhertu has been approved in the US for the treatment of adult patients with certain types of inoperable breast cancer that has progressed on one or more endocrine therapies. The drug, also known as fam-trastuzumab deruxtecan-nxki, has specifically been approved for use in...
Fundstrat's Tom Lee Sees Nvidia's 17% Plunge As An 'Opportunity,' Calls Nasdaq's Over 600 Points Plunge Drop A Market 'Overreaction'
Fundstrat's Tom Lee Sees Nvidia's 17% Plunge As An 'Opportunity,' Calls Nasdaq's Over 600 Points Plunge Drop A Market 'Overreaction'
Jan 28, 2025
Fundstrat Global Advisors‘ head of research Tom Lee believes Monday’s massive tech sector sell-off, which saw Nvidia Corp. ( NVDA ) shares plunge 17%, represents a buying opportunity rather than a fundamental shift in the artificial intelligence landscape. What Happened: “To me, it’s an overreaction,” Lee told CNBC’s “Closing Bell,” comparing the drop to Nvidia’s March 2020 decline that proved...
Copyright 2023-2026 - www.financetom.com All Rights Reserved